Kisspeptin-10, the KISS1R-GnRH neuron link, and what the published human fertility literature actually uses

Key takeaways

• Kisspeptin is encoded by KISS1 and signals through KISS1R (formerly GPR54). It is the upstream activator of GnRH neurons in the hypothalamic arcuate and preoptic nuclei. Loss-of-function KISS1R variants cause normosmic hypogonadotropic hypogonadism in humans, which established the pathway's clinical importance .
• The kisspeptin family includes the parent kisspeptin-54 (KP-54), kisspeptin-14 (KP-14), kisspeptin-13 (KP-13), and the C-terminal decapeptide kisspeptin-10 (KP-10). All four share the same C-terminal RF-amide motif that activates KISS1R, but they differ substantially in circulating half-life .
• The published human trial literature is dominated by KP-54, used at the Imperial College London program of Dhillo and Abbara and the Edinburgh program of Jayasena and Skorupskaite. Kisspeptin-54 has been used investigationally as an ovulation trigger in IVF, as a probe of hypothalamic amenorrhea, and as a tool for studying GnRH pulse generation .
• Kisspeptin-10 has a very short circulating half-life (minutes), which is why the human trial program preferentially uses KP-54 for sustained dosing. Research-vial KP-10 product sold to the community is not the peptide that the IVF trigger trials used and is not interchangeable with KP-54 by dose .
• No kisspeptin product is FDA-approved. KP-10 and KP-54 are both investigational; clinical use is restricted to registered trial protocols. The FDA's bulk substances posture applies to research-vial kisspeptin preparations sold to the community .

What kisspeptin is and how it was discovered

KISS1 was originally identified in 1996 as a metastasis suppressor gene in melanoma. The peptide product was named for the town of Hershey, Pennsylvania, where the discovering laboratory worked and the famous Hershey's Kisses chocolate was made. The reproductive role of kisspeptin emerged later, when independent groups reported that loss-of-function variants in GPR54 (now KISS1R) caused hypogonadotropic hypogonadism in human pedigrees. That established kisspeptin as the missing upstream activator of GnRH neurons .

In the current model, kisspeptin neurons in the arcuate nucleus generate the pulse pattern of GnRH release through coordinated firing, integrating estrogen and androgen feedback. Kisspeptin neurons in the anteroventral periventricular nucleus mediate the preovulatory LH surge in females. KISS1R activation on GnRH neurons triggers GnRH release into the hypophyseal portal system, which drives LH and FSH release from the anterior pituitary. The downstream gonadal axis follows from that signal.

KP-54 versus KP-10: why the literature uses one and the community uses the other

The parent peptide kisspeptin-54 (KP-54) is the 54-residue mature form processed from the KISS1 precursor. Shorter forms (KP-14, KP-13, KP-10) share the C-terminal RF-amide that contains the receptor-binding motif. In receptor assays, all of these fragments activate KISS1R with similar intrinsic potency. The clinical difference is half-life and exposure shape .

Kisspeptin-10 has a circulating half-life on the order of a few minutes in humans. After a bolus intravenous dose, the LH response is sharp and short, which is useful for probing single GnRH pulses but inconvenient for sustained physiological dosing. Kisspeptin-54, by contrast, has a circulating half-life on the order of hours after subcutaneous administration, which makes it tractable for sustained activation in a controlled trial setting. Most of the human trial program uses KP-54 for that reason .

• Trial protocols for IVF triggers, hypothalamic amenorrhea probes, and pubertal-axis stimulation typically use kisspeptin-54 (KP-54).
• Mechanism-of-action and single-pulse studies often use kisspeptin-10 (KP-10) intravenously in a research setting.
• Research-vial peptide product sold as KP-10 to the community is not the same molecule as the KP-54 used in the published efficacy trials.
• Equivalence between KP-10 doses and KP-54 doses is not established. Dose conversion based on receptor potency alone ignores the exposure-shape difference.

What the human trial program has actually shown

The Imperial College London group around Waljit Dhillo and Ali Abbara has run the most consistent human kisspeptin trial program. The 2005 first-in-human work (Dhillo WS, Chaudhri OB, Patterson M, et al., Journal of Clinical Endocrinology and Metabolism) showed that intravenous KP-54 in healthy men raised circulating LH and FSH, establishing the human pharmacology of the upstream pathway .

Subsequent work explored kisspeptin in women across the menstrual cycle, in women with functional hypothalamic amenorrhea, and in IVF cycle triggering. The Abbara 2015 paper (Journal of Clinical Investigation) used kisspeptin-54 as the ovulation trigger in an IVF protocol and reported viable oocyte retrieval and live births, framing kisspeptin as a candidate alternative to hCG triggering in women at high risk of ovarian hyperstimulation syndrome .

Edinburgh-based work by Karolina Skorupskaite, Richard Anderson and colleagues has used kisspeptin to probe GnRH pulse generation across reproductive phases and in the context of hypothalamic amenorrhea. Those studies are mechanism-rich rather than efficacy-focused; they map how the kisspeptin signal interacts with neurokinin B and dynorphin (the KNDy neuron network) to set the GnRH pulse pattern .

What KP-10 actually does in research protocols

Kisspeptin-10 is the typical peptide used when investigators need a sharp, short LH response in a research setting. A bolus intravenous KP-10 dose produces a transient LH rise that peaks within roughly 20 to 30 minutes and returns to baseline within an hour. That kinetic profile is well-suited to single-pulse experiments, GnRH-neuron-stimulation probes, and acute mechanism-of-action work. It is poorly suited to sustained physiological replacement, which is the use case for KP-54 .

Community use of subcutaneous KP-10 as a long-acting libido or fertility-supporting peptide is not supported by the pharmacokinetic literature. Subcutaneous bioavailability and half-life of KP-10 have not been characterized to label-grade standards, and the IVF-trigger and amenorrhea trial data that the community sometimes cites in defense of KP-10 protocols comes from KP-54 work, not KP-10 work. The honest framing is that KP-10 is a research probe for single-pulse pharmacology, not a documented sustained-activation therapy.

What kisspeptin therapy is not (yet)

• Not an FDA-approved product. No kisspeptin label, no KP-10 label, no KP-54 label.
• Not a documented standalone fertility treatment outside registered trial protocols.
• Not a documented testosterone-replacement strategy. The HPG-axis activation hypothesis is plausible mechanistically, but no Phase 3 trial supports kisspeptin as a primary therapy for male hypogonadism.
• Not a libido drug. Some early kisspeptin work has measured arousal endpoints in research settings, but the clinical data does not support a routine sexual-health protocol.
• Not interchangeable across fragments. KP-10 and KP-54 are pharmacokinetically distinct, and trial data on one does not automatically extend to the other.

For research and educational purposes only. Not medical advice. Decisions about reproductive or HPG-axis therapy should involve a qualified clinician who can interpret diagnostic context, baseline gonadal status, and the gap between investigational kisspeptin protocols and approved therapies.

Regulatory and research-vial context

Kisspeptin-10 and kisspeptin-54 are both investigational worldwide. The FDA's posture on peptide bulk substances applies to research-vial kisspeptin sold to the community; identity, purity, and dose accuracy of those preparations cannot be assumed from the published trial literature, which used regulated investigational supply with characterized analytical certificates .

Editorial summary

Kisspeptin is the upstream switch of the HPG axis, encoded by KISS1, signaling through KISS1R, driving GnRH neuron firing. The human trial program is real and growing, with a credible IVF-trigger result for KP-54, mechanism-rich amenorrhea work, and a clear distinction between KP-54 (sustained exposure) and KP-10 (sharp short pulse). The decapeptide that the research community calls KP-10 is not the peptide that the IVF-trigger and amenorrhea trials used, and no version of the molecule is FDA-approved. Article-quality coverage of kisspeptin therefore lands on pathway biology, the KP-54 trial corpus, and the gap between trial peptide and research-vial peptide.

Related tools

• Protocol builder overview - Public overview of the Pro protocol builder.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.